Statement on the Use of Conjugate Pneumococcal Vaccine - 13 Valent in Adults (Pneu-C-13): An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. Invasive Pneumococcal Disease Epidemiology and Conjugate Vaccines in Canada, 2000-2019.JAMA network open · 2026
   Article
2. Evaluating the cost-effectiveness of a sequential pneumococcal vaccination compared to single-dose vaccination strategy for adults in Hong Kong.Human vaccines & immunotherapeutics · 2020
   Article
3. Vaccine strategies for prevention of community-acquired pneumonia in Canada: Who would benefit most from pneumococcal immunization?Canadian family physician Medecin de famille canadien · 2019
   Review
4. Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults.Canadian journal of public health = Revue canadienne de sante publique · 2018
   Article
5. Long-term trends in invasive pneumococcal disease in Manitoba, Canada.Human vaccines & immunotherapeutics · 2017
   Article
6. A fatal case of pneumococcal sepsis years after splenectomy.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2017
   Article
7. Forecasting Trends in Invasive Pneumococcal Disease among Elderly Adults in Quebec.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2017
   Article
8. Summary of NACI Statement: Interim Recommendations on the Use of Pneumococcal Vaccines in Immunocompetent Adults 65 Years of Age and Older.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2016
   Article
9. Whole-genome Sequencing for Surveillance of Invasive Pneumococcal Diseases in Ontario, Canada: Rapid Prediction of Genotype, Antibiotic Resistance and Characterization of Emerging Serotype 22F.Frontiers in microbiology · 2016
   Article
10. Effects of a pharmacy-driven perisplenectomy vaccination program on vaccination rates and adherence to guidelines.The Canadian journal of hospital pharmacy · 2014
    Article
11. How many individuals with asthma need to be vaccinated to prevent one case of invasive pneumococcal disease?The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2014
    Article
12. The role of pharmacists in providing recommended vaccines.Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC
    Review
13. Opportunities for pharmacists in vaccinating higher-risk populations.Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC
    Review
14. The epidemiology of invasive pneumococcal disease in older adults from 2007 to 2014 in Ontario, Canada: a population-based study.CMAJ open
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.